ZSP1603 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	2

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05119972 (ClinicalTrials.gov)	October 21, 2021	9/10/2021	Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	A Multi-center, Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, PK and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Drug: ZSP1603;Drug: Placebo	Guangdong Raynovent Biotech Co., Ltd	NULL	Recruiting	40 Years	N/A	All	36	Phase 1/Phase 2	China
2	NCT03619616 (ClinicalTrials.gov)	July 16, 2018	23/7/2018	Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults	A Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy Subjects	Idiopathic Pulmonary Fibrosis(IPF);Solid Tumor	Drug: ZSP1603 7.5 mg;Drug: ZSP1603 12.5 mg;Drug: Placebo 12.5mg;Drug: ZSP1603 25 mg;Drug: Placebo 25mg;Drug: ZSP1603 50 mg;Drug: Placebo 50mg	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	NULL	Completed	18 Years	50 Years	All	40	Phase 1	China